Pieter Imhof appointed Chief Executive Officer BioBTX B.V.

GRONINGEN, 25 September 2017 – BioBTX B.V. has announced that starting 15 September 2017 Mr. Pieter Imhof has been appointed Chief Executive Officer (CEO) of BioBTX BV. In this role Mr Imhof will especially focus on the further upscaling and commercialization of the BioBTX technology.

Read more ...

Carduso Capital invests in “Gum Irrigator”

Gum Irrigator B.V. is a family holding based in Groningen, the Netherlands. The Gum Irrigator apparatus provides an effective, pain-free and non-invasive solution in the treatment of gum problems with natural teeth (periodontitis) and implants (peri-implantitis). Therefore, the Gum Irrigator will provide easier access to subgingival cleaning to a larger part of the population. According to the statistics of the World Health Organization 15-20% of the adult population suffers from severe gum problems.

Read more ...

Carduso Capital Groningen invests in DEAM Holding BV.

DEAM is a young company co-based in Groningen that develops precision medical devices, specialising in steerable, minimally invasive instruments. The DEAM instruments are steerable in all directions, making it possible for surgeons to get an optimal operating position, also in areas that are not easy to reach or access. The DEAM steerable instruments offer great benefits in combination with the latest 3D-imaging technologies used during surgery.

Read more ...

Carduso Capital invests in BioBTX

Press release

BioBTX is a company based in Groningen-NL that produces chemicals (Aromatics) from Biomass. This technique allows the manufacturing of ‘green' plastics. BTX stands for benzene, toluene and xylene. These chemicals are normally extracted from natural crude oil and form the building blocks for plastics. BioBTX developed a way in which the oil can be replaced by biomass.

Read more ...

Carduso Capital Groningen invests in BiOrion Technologies BV

Press release

Carduso Capital Groningen invests in BiOrion Technologies BV, a spin-off company of the University of Groningen.

BiOrion Groningen is a biopharmaceutical company that develops products for the diagnosis and treatment of fibrosis, the process of formation of excess fibrous connective tissue in organs such as liver, kidney, heart or lungs by which they may turn-out completely. BiOrion has raised additional capital from the Carduso Capital investment Fund for the clinical validation of its proprietary drug-targeting technology.

Read more ...
Page 1 of 2